CTLA4 and cancer: In line with this thought, the approval of ipilimumab, a monoclonal antibody against CTLA4, for the treatment of late-stage melanoma in 2011 by the US Food and Drug Administration (FDA) has been the breakthrough in the emergence of cancer immunotherapy (8).